Sensorion's Significant Participation in Gene Therapy Congress
Sensorion is set to demonstrate its commitment to innovative therapies by participating in the upcoming annual gathering of the European Society of Gene and Cell Therapy (ESGCT). This prestigious event is a focal point for leading researchers in genetic therapies and is keenly anticipated. Its scientific team is excited to present several insightful posters detailing its research, particularly on its GJB2-GT gene therapy drug candidate.
Insights on Advancements in Auditory Therapies
Focus on GJB2-GT Development
At this Congress, Sensorion will showcase the latest developments in its GJB2-GT program, a novel approach aimed at treating deafness linked to mutations in the GJB2 gene. These mutations are known to be the prevalent cause of hearing loss in children, making this research vital for patients and their families. The presentation holds the potential for revolutionizing therapeutic strategies in treating hearing disorders.
Expert Contributions Enhance Research Impact
Professor Christine Petit, a prominent figure in auditory research and esteemed member of Sensorion's Scientific Advisory Board will take the lead in presenting findings from pre-clinical mouse models. Her work will focus on the therapeutic responses generated from GJB2 gene therapy, which will be vital for advancing our understanding of this genetic disorder’s treatment lifecycle.
Structured Presentations with Notable Posters
Three key posters will highlight critical aspects of the GJB2-GT program, detailing research that encompasses various stages of the therapy's development. Sandra Pierredon, a key scientist from Sensorion's Technology and Innovation Platform department, will collaborate with the Institut Pasteur. She will present essential characterizations of a safe and functional gene therapy vector aimed at addressing DFNB1A, a hereditary form of deafness.
Preclinical Development Insights
Further, Laurent Désiré, who leads Sensorion's Preclinical Development efforts, will delve into the steps involved in preclinical development for GT-GJB2. This research will discuss the application of adeno-associated vectors in gene therapy, illuminating the potential pathways for successful treatment of DFNB1A hearing loss.
Research Availability and Future Directions
On display from October 22 to October 23, the posters will later be accessible through Sensorion's website for those who wish to explore further insights on these important studies. The conversation around hearing loss therapies continues to evolve, and Sensorion is spearheading efforts to bring effective treatments to light.
About Sensorion: Pioneering Hearing Loss Solutions
Sensorion, identified by its ISIN FR0012596468 and mnemonic ALSEN, stands at the forefront of biotech innovation aimed at restoring and treating hearing loss disorders. The company's dedication to addressing unmet medical needs is clear through its robust R&D initiatives, bolstered by strategic collaborations with institutions like the Institut Pasteur.
Exploration of Gene Therapy Programs
Sensorion is making strides with two critical gene therapy programs targeting hereditary deafness. The program SENS-501 (OTOF-GT) is currently in clinical trials, while GJB2-GT shows promise in tackling hearing loss related to GJB2 gene mutations. Additionally, the company is actively identifying biomarkers to enhance diagnosis and treatment effectiveness for these challenging conditions.
Expanding Clinical-Stage Portfolio
Beyond gene therapy, Sensorion offers clinical-stage small molecule programs designed to treat various hearing disorders. SENS-401 (Arazasetron) is progressing through Phase 2 studies aimed at mitigating Cisplatin-Induced Ototoxicity and has also been evaluated in patients undergoing cochlear implantation. The outcomes of these trials will be pivotal in shaping future therapeutic solutions.
Frequently Asked Questions
What is the GJB2-GT program about?
The GJB2-GT program aims to provide gene therapy solutions for hearing loss associated with mutations in the GJB2 gene.
Who is leading the poster presentations at the Congress?
Professor Christine Petit, an esteemed figure in auditory research, will lead the presentations.
Where can I find the poster details after the presentation?
The details of the posters will be accessible on Sensorion's official website shortly after the session concludes.
What are the clinical-stage programs Sensorion is pursuing?
Sensorion is developing gene therapies like SENS-501 and gene therapy programs focusing on various forms of hereditary deafness.
How does Sensorion impact the field of hearing loss therapies?
Sensorion pioneers innovative therapies addressing major gaps in the treatment of hearing loss, contributing significantly to research and potential solutions.
